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Bone and skeletal muscle mass are highly correlated in mammals, suggesting the 
existence of common signaling networks that serve to coordinate the development of 
these two anatomically adjacent tissues.  Myostatin and its related activin ligands of the 
TGB-beta superfamily are known regulators of skeletal muscle mass and are also 
expressed in bone. Given the well-established role of myostatin in muscle, these ligands 
may serve a similar function in bone.  To investigate the role of this pathway in bone, 
pharmacological and genetic approaches were employed to determine the role of activin 
receptor signaling in bone.   
To identify which components of the activin signaling pathway were expressed in 
bone, we used immunohistochemistry. ACVR2A and ACVR2B were localized to 
osteoblasts and osteocytes in both trabecular and cortical bone.  Primary mouse calvarial 
osteoblasts also expressed the major activin receptor signaling components, including 
ACVR2A, ACVR2B, and ACVR1B (ALK4). Furthermore, upon exposure to activin 
ligands, osteoblasts demonstrated active signaling by increased levels of phosphorylated 
Smad2/3.  Osteoblasts deficient in ACVR2A by Cre-mediated recombination exhibited 
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accelerated differentiation, evidenced by increased alkaline phosphatase activity, mineral 
deposition, and increased transcriptional expression of Osterix, Osteocalcin, and Dmp1 
compared to controls.  To determine the importance of activin receptor signaling in bone 
in vivo, we analyzed the skeletal phenotypes of mice selectively deficient in ACVR2A 
and ACVR2B in osteoblasts and osteocytes (osteocalcin-Cre).  Whereas ACVR2B 
deficient mice (Ob.ACVR2B-/-), had no significant changes in bone parameters, mice 
lacking ACVR2A (Ob.ACVR2A-/-) had significantly increased femoral trabecular bone 
volumes at six and twelve weeks of age.  In addition, Ob.ACVR2A-/- mice also exhibited 
increases in cortical parameters at twelve weeks of age, which resulted in enhanced 
mechanical properties.  Compound mutant mice lacking both ACVR2A and ACVR2B 
demonstrated increases in trabecular bone volumes similar to Ob.ACVR2A-/- mice.  
Taken together, these data indicate that activin receptor signaling in osteoblasts is 
predominantly mediated through ACVR2A and acts as a negative regulator of bone mass.   
We then evaluated activin-targeted biologics for their efficacy in muscle and bone 
healing.  Therapeutic potential of soluble activin receptor administration was investigated 
utilizing a composite musculoskeletal injury model, consisting of a pin-stabilized femur 
osteotomy and an overlying volumetric muscle defect.  With ACVR2B/Fc treatment, the 
bone fracture callus volume and mineral content were significantly increased as 
compared to vehicle controls while mechanical properties were unchanged between 
groups.  Furthermore, muscle mass was significantly increased while injury fibrosis and 
fat infiltration were reduced with ACVR2B/Fc administration –  supporting the 
possibility of using soluble activin receptors as a dual muscle and bone anabolic agent. 
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In conclusion, the results from these studies demonstrate that the activin signaling 
pathway occurs primarily through ACVR2A in osteoblasts and acts to negatively regulate 
bone mass.   Furthermore, inhibition of this pathway may act as a dual anabolic agent and 
is a potential therapeutic to augment composite muscle and bone healing. 
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1.1 Overview of Skeletal Biology and 
Repair 
The skeleton is a highly specialized organ system that facilitates locomotion, 
mineral homeostasis, and the protection of vital organs.  Bone is a composite tissue 
comprised of both organic and inorganic components that are constantly renewed and 
replaced by resident bone cells. [1, 2] Type I collagen is the predominant organic 
component of the bony extracellular matrix and acts as a scaffold for mineral nucleation.  
This mineral phase endows a rigid structure and mechanical strength to the underlying 
collagen, in addition to acting as a repository for calcium, magnesium, and phosphate 
ions necessary for homeostasis. [3]  
The skeleton is composed of over 200 individual bones that are classified into 
four distinct categories: short, long, irregular, and flat.  Together with cartilage, they form 
the axial and appendicular skeleton that we know and recognize.  Each of these bones 
develop in utero and grow postnatally through either intramembranous or endochondral 
ossification. During embryological development, bone formation begins with the 
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condensation of mesenchymal precursors at primitive, anatomic bone sites to form the 
skeleton template.  Intramembranous ossification occurs at sites of flat bone formation, 
such as the skull and sternum. During this process, mesenchymal progenitor cells 
differentiate directly into osteoblasts to form primary ossification centers. [4, 5]  In 
contrast to flat bones, long and short bones develop via endochondral ossification – 
where progenitor cells first differentiate into chondrocytes that form an initial cartilage 
template.  As these chondrocytes proliferate and subsequently hypertrophy, they begin to 
secrete the extracellular matrix components necessary for cartilage development. [5, 6] 
Osteoprogenitor cells, vascular endothelial cells, and hematopoietic stem cells then 
invade this preliminary cartilage to initiate mineralization.  Further angiogenesis occurs 
within the cartilage template while newly formed osteoblasts begin to secrete osteoid – 
unmineralized extracellular matrix containing primarily collagen type I.  Differentiated 
osteoblasts then facilitate mineralization of newly formed osteoid through the deposition 
of hydroxyapatite onto the bone matrix to form the calcified skeleton. [7-9]  
Skeletal tissues are categorized into two distinct architectures, cortical and 
trabecular bone.  These bone compartments are distinct in their structure and function as 
cortical bone is very dense and is the primary form found within the shaft of long bones, 
providing ample strength to these tissues.  Trabecular bone, however, is much less dense 
and organized into intersecting trabeculae that give a spongy appearance when viewed 
grossly.  The high surface area of trabecular bone allows for rapid mineral metabolism 
and calcium homeostasis.  Trabecular bone is typically found in the epiphyses of long 
bones, proximal to the growth plate, and provides compressive strength to the proximal 
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and distal portions of the long bones. [2, 10] While the cortical and trabecular bone 
compartments are uniquely distinct in shape, together they function as one unit providing 
mechanical strength, stability, and a mineral reservoir.  
Skeletal tissue is populated by three primary cell types – osteoblasts, osteocytes, 
and osteoclasts – each with distinct functions.  Together, they work in concert to model 
the bone during development and remodel bone throughout adult life.  Osteoblasts, which 
are derived from mesenchymal precursors, function to produce an extracellular collagen 
matrix and facilitate matrix mineralization. [11] A distinct proportion of these osteoblasts 
then become entombed in mineral, where they differentiate into osteocytes, comprising of 
over 90-95% of all cells in the skeleton. [12, 13] Osteocytes are connected to all other 
bone cells via their dendritic processes that channel through bone canaliculi to form an 
extensive cellular network.  Although the precise functions of the osteocyte are not clear, 
most evidence suggests that they are responsible for sensing mechanical loads and more 
recently, participate in mineral metabolism. [12] The third bone cell type is the osteoclast 
– large, multinucleated cells that originate from bone marrow macrophages and 
monocytes.  These cells are responsible for the removal of bone through degradation of 
the organic and inorganic components of the skeleton. [2, 10, 14] Utilizing a ruffled 
membrane to create an isolated extracellular microenvironment, osteoclasts acidify the 
underlying calcified tissue to liberate inorganic mineral and subsequently degrade the 
remaining organic proteins. [15]   
Together, these three cells work in concert to remodel the skeleton through the 
coupling of bone formation and resorption.  This continual renewal of calcified tissues 
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allows microdamaged bone to be replaced to maintain the health and integrity of the 
skeleton while ensuring homeostatic serum mineral levels. 
1.2 Physiology of Fracture Healing 
Bone fractures are the most common traumatic injuries.  While many of these 
injuries will go on to repair themselves with reduction and setting, approximately ten 
percent will not heal properly.  Non-unions and critically sized defects further result in 
devastating consequences in morbidity and mortality. [16, 17] Unlike many other tissue 
repair processes, fracture healing closely mirrors many of the embryological events, 
including endochondral and intramembranous ossification, that occur during primary 
development. [18, 19] Bone fractures lead to profuse bleeding and hematoma formation 
at the site of injury.  From there, inflammatory cytokines, including tumor necrosis 
factor-α and interleukins -1, -6 -11, and -18, are released into the injury site to recruit 
inflammatory cells and prime the environment for repair.  Mesenchymal stem cells 
(MSC) derived from a number of sources including the bone marrow [20], muscle [21], 
periosteum [22], and general circulation [23] are then recruited to the injury site.  Within 
the skeletal injury, there is also a differential in oxygen tension with the lowest oxygen 
concentration in the center of the fracture and highest oxygen tensions distally, where the 
blood supply remains intact.  Because of this differential, endochondral ossification 
occurs in the center of the fracture while intramembranous ossification occurs closest to 
the bone ends, where oxygen tension is highest.  Tissue hypoxia within the center of the 
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fracture site induces MSC differentiation into chondrocytes to create a soft, 
unmineralized callus.  Hypoxia also induces vascular invasion and angiogenesis to restore 
perfusion.  As the cartilage develops, resident chondrocytes hypertrophy and eventually 
terminally differentiate.  The newly formed matrix is then mineralized, forming transient 
immature woven bone.  Osteoblasts and osteoclasts then remodel the callus to transform 
the disorganized, woven bone into hardy, lamellar bone that recapitulates the original 
anatomic structure. [2, 17, 24, 25] (Figure 1.1)  
Figure 1.1: Physiology of Fracture Repair 
The major events in the progression of bone fracture healing with the primary cell 
types present at each stage. [10]   
Note: Reproduced with permission from “Fracture healing: mechanisms and 
interventions” by T.A. Einhorn and L.C. Gerstenfeld, 2015, Nature Reviews 
Rheumatology 11, 45-54. Copyright 2014 by Nature Publishing Group. 
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1.3 Overview of Skeletal Muscle Biology 
The counterpart to the rigid skeleton is the adjacent skeletal muscle, the most 
abundant tissue of the human body.  Together, they enable the coordinated movements of 
daily life.  Skeletal muscle is organized into hierarchical structures consisting of 
myofibers that contract together to act as individual functional units.  Each myofiber is 
formed by the fusion of several myoblasts to create a multinucleated fiber and is 
composed of several smaller myofibrils.  These myofibrils contain multiple repeating 
sarcomeres – the fundamental unit of muscle contraction.  Each sarcomere contains the 
longitudinal arrangement of the contractile proteins actin and myosin to form the thin and 
thick filaments, respectively.  These filaments slide past one another during the 
contraction cycle and their coordinated summation generates the locomotion of the 
human body. [26, 27] 
Like the primitive skeleton, skeletal muscle originates from mesenchymal 
precursors, in particular the paraxial mesoderm.  During embryogenesis, a portion of the 
mesoderm clusters into distinct somites that form the dermatomyotome and later form 
separate myotomes.  These myotomes contain skeletal muscle progenitor cells that 
migrate to the limb buds and areas of axial muscle development.  The progenitor cells 
then expand and differentiate into myocytes under the direction of myogenic regulatory 
factors (MRFs) and other transcription factors that regulate myogenesis. [28] The newly 
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formed myocytes then fuse and mature into multinucleated muscle fibers to form distinct 
muscle groups. [27, 29] 
1.4 Muscle and Bone Interactions 
Mature bone is subject to continuous remodeling throughout life.  This cycle of 
bone resorption and formation works to remove damaged skeletal tissue and maintain 
serum calcium levels, but also allows continual skeletal adaptations to hormonal and 
mechanical cues.  These skeletal changes are highly correlated with the adjacent 
musculature with peak bone mass accompanying peak muscle mass.  Conversely, the 
opposite is also evident as osteopenia and sarcopenia nearly always coexist. [30-34] 
Studies investigating spinal cord injuries have demonstrated that severe muscle atrophy 
nearly always is accompanied by significant bone loss directly beneath the muscle lesion. 
[35, 36] Furthermore, implanted electrical stimulators that can induce muscle 
contractions will partially prevent spinal cord injury-induced bone loss. [37] This in-step 
synchronization suggests that there are common mechanical and paracrine regulatory 
pathways that exist between muscle and bone, enabling their coordination in form and 
function.  
 The prevailing notion for the coordination between muscle and bone is that this 
relationship is mediated through mechanical forces – either emanating from the 
surrounding muscles or from physical impact. [38] For any particular movement, bones 
act as rigid levers that allow muscles to contract and pull against, enabling the complex 
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movements of daily living.  The skeletal response to muscle contractions has been well-
documented and was described by early pioneers such as Julius Wolff.  His theory, which 
would be later known as Wolff’s Law, states that the skeleton will continually adapt to 
the various loads under which it is placed.  These ideas were taken further and later 
integrated into Harold Frost’s mechanostat theory, where elastic mechanical deformation 
of bone allows the skeleton to adapt and withstand the maximum forces experienced. [39-
42] This process of skeletal adaptation occurs in both loading and unloading scenarios.  
Adaptation is particularly important in instances of uncontrolled bone loss such as 
osteoporosis, as interventions that induce mechanical loading, including exercise and 
vibration therapy, prevent bone loss.  In both Wolff’s and Frost’s theories, mechanical 
loading is the most important determinant of the geometry and strength of the skeleton 
and is a primary link between muscle and the bone beneath it. 
This link is evident in adult life, where physical activity and loading experienced 
in sports or exercise are known to impact these two tissues.  In several studies that 
compared the musculoskeletal systems of active individuals to those of sedentary 
individuals, subjects that competed in sports and weight-bearing exercises had 
significantly higher bone mineral density as well as muscle function. [43-47] Interesting, 
while it was assumed that this correlation between mechanical forces from muscles and 
bone strength was a post-natal phenomenon, recent evidence from Zelzer et al has 
demonstrated that mechanical adaptation occurs even in utero.  Using genetic muscle 
paralysis models, their group has shown that fetal muscle contractions are necessary for 
bone shaping and that the bone geometrical outline is lost with muscle paralysis.  Without 
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these muscle-derived forces, the resulting bones are mechanically inferior and are unable 
to optimize to their load-bearing capacity. [48] Likewise, the physical forces created by 
muscle contractions are also necessary for proper joint development. Other studies have 
demonstrated that administration of neuromuscular blocking agents during limb 
development impairs proper joint formation, further supporting the notion that the 
interaction between muscle and bone tissue is necessary for proper musculoskeletal 
development. [49] The findings of these studies as well as loading studies previously 
discussed suggest that the coordination been muscle and bone mass is largely dependent 
on the mechanical forces between these two tissues. 
While the precise biological signals that transduce these mechanical events are 
unknown, these signals are likely to utilize common regulatory pathways.  Because 
muscle and bone develop from the same embryological origins, there are several 
overlapping growth factors and morphogens that are shared in muscle and bone 
development.  For instance, the Wnt [50-52], Growth Hormone/Insulin-like Growth 
Factor (GH/IGF) [53-55], and Notch [56-58] pathways all play critical roles in muscle 
and bone development and homeostasis.  In the case of the GH pathway, IGF1 acts as a 
potent inducer of muscle hypertrophy and also plays a central role in the differentiation of 
osteoblasts into osteocytes to promote bone formation. [59-61] Likewise, other studies 
suggest a role for other molecules, such as vitamin D, in muscle and bone development. 
[62-64] Locally produced vitamin D exerts its effects in both an autocrine and paracrine 
manner to modulate bone remodeling by enhancing osteoblast differentiation and 
mineralization. [65-67] However, apart from its role in bone, vitamin D has also been 
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implicated in muscle homeostasis.  In mouse models in which the vitamin D receptor was 
eliminated, the corresponding skeletal muscle was approximately 20% smaller and these 
mice exhibited impaired motor coordination. [68, 69] While the exact mechanism of 
vitamin D’s role in skeletal muscle has yet to be elucidated, there are clear associations 
between vitamin D and muscle performance.  These example ligands are just a few of the 
many overlapping signaling pathways that function in muscle and bone tissues.    
Because of the significant overlap in regulator pathways, one or more of these 
pathways are likely responsible for the synchronization of bone and muscle.  Even in the 
case of mechanical stimulation, the physical forces emanating from the surrounding 
musculature are translated into a biological signal and one of these pathways likely 
mediates that response.  In fact, new studies describe the first direct evidence of crosstalk 
between muscle and bone as demonstrated during development.  Olwin et al have shown 
that Indian Hedgehog, a bone-derived signaling molecule, is necessary for secondary 
myogenesis in the developing chick hindlimb.  Indian Hedgehog from the developing 
bone acts directly on myoblasts to regulate muscle precursor apoptosis. [70] This study is 
the first to establish a direct communication between muscle and bone tissues in 





1.5 Activin Signaling as a Potential 
Mechanism Coupling Muscle and Bone 
The transforming growth factor-beta (TGF-β) superfamily is an important 
signaling pathway that is common to muscle and bone regulation.  TGF-β ligands are 
comprised of over forty members and are divided into three main sub-families that 
include TGF-βs, bone morphogenic proteins (BMPs), and activins. [71] The TGF-β 
pathway is responsible for many critical cellular processes such as proliferation, 
differentiation, morphogenesis, and tissue regeneration.  However, the realization of 
TGF-β ligands’ paradoxical nature – being both a stimulator and inhibitor, depending on 
condition – revealed more sophisticated levels of complexity in signaling that are time, 
concentration, and target cell specific. [72, 73] These layers of intricacy have made it 
difficult to succinctly describe the TGF-β pathway but have enriched our understanding 
of the multifunctional capabilities of TGF-β ligands.   
In canonical TGF-β signaling, ligands first bind to dimerized, cognate type II 
receptors.  This binding then recruits complementary type I receptors to form a 
heterotetrameric signaling complex.  Proximity of these receptors then allows the Ser/Thr 
kinase domains of the type II receptors to transphosphorylate the nearby type I receptors.  
This phosphorylation event activates the type I receptors to then recruit secondary 
messengers (receptor-Smads), which are in turn phosphorylated by the activated type I 
receptors.  These secondary messengers signal through receptor-Smads 2/3, in the case of 
TGF-βs and activins, or receptor-Smads 1/5/8 in the case of BMPs. [72-74] Following the 
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TGF-β signaling cascade, phosphorylated Smad 2/3 then interacts with Runx2, the master 
transcriptional activator of osteoblast differentiation, to control mesenchymal precursor 
differentiation. [75] TGF-β superfamily ligands have been widely recognized to be 
critical in mammalian development and are necessary for proper embryogenesis.  For 
instance, during embryogenesis, an asymmetric BMP gradient is created to enable dorsal 
patterning and form the dorsal-ventral axis of the embryo. [76] In addition to embryo 
patterning, TGF-β ligands have also been widely implicated in skeletal development and 
homeostasis as disruptions in TGF-β signaling have been linked to multiple 
musculoskeletal diseases as well as cancer metastases.  [77, 78] 
TGF-β signaling is primarily responsible for the maintenance and expansion of 
the progenitor pool necessary for osteoblast formation. [78] Skeletal tissues, including 
bone and cartilage, contain large amounts of deposited inactive TGF-β that, when 
released and activated, can act on target cells.  TGF-β ligand is stored within the 
extracellular matrix in a latent form.  When TGF-β ligands are first synthesized, they 
interact with a latency associated peptide (LAP), which then binds to several other 
proteins to form the large latent complex (LLC).  This inactive LLC is secreted into the 
extracellular matrix in skeletal tissues and awaits activation and release. [79] Latent TGF-
β can be activated in a number of different ways but is broadly categorized as either 
integrin-independent or integrin-dependent mechanisms.  Integrin-independent 
mechanisms of activation include cleavage by metalloproteases, acidification, or 
exposure to reactive oxygen species. [80-82] Integrin-dependent mechanisms primarily 
function through the αVβ6 integrin. [83, 84] This location specific TGF-β activation 
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enables dynamic microenvironment changes to regulate the balance of osteoblast and 
osteoclast differentiation at specific sites of bone remodeling.  Through this mechanism, 
TGF-β is able to closely balance bone formation with bone resorption, enabling site-
specific adaptations to physical and hormonal cues.   
While the TGF-β ligands are known to regulate bone homeostasis and 
maintenance, other members of the TGF-β superfamily, such as BMPs, are also known 
for their role in skeletal development.  The vertebrate skeleton, which is composed of 
cartilage and bone, is derived from many embryonic lineages.  Progenitor cells from the 
neural crest, paraxial mesoderm, and lateral plate mesoderm expand and consolidate into 
mesenchymal condensations that will form the template of the future skeletal sites. [85] 
This process is governed by many different growth factors and morphogens but the 
BMPs play a primary role in skeletal development by regulating osteoblast and 
chondrocyte differentiation, cartilage and bone formation, and axial patterning.  In 
vertebrates, mesodermal cells develop into the paraxial mesoderm, which is then 
segmented in a rostral-caudal progression to form distinct somites.  This patterning, 
anterior–posterior, dorsal–ventral, and proximal–distal, is predominately mediated by 






1.6 Activins and Their Receptors 
Activins are integral signaling components of the gonadal endocrine system and 
act primarily as stimulants of ovarian follicle maturation in females and spermatogenesis 
in males.  Activins were first identified in purification fractions of ovarian follicular fluid 
and shown to strongly induced follicle-stimulating hormone (FSH) release. [88] Since 
being first identified, many other non-gonadal functions of activins have also been 
identified, including erythropoiesis, immune function, wound repair, liver proliferation, 
and angiogenesis. [89]  
In the context of skeletal muscle, one of the most well-known activin ligands is 
myostatin as it has been discovered to be one of the most potent regulators of skeletal 
muscle.  Myostatin was first described by Dr. Se-Jin Lee and colleagues in 1994 as a 
secreted protein that is made exclusively by skeletal muscle and acts as a negative 
regulator of muscle mass.  Furthermore, with myostatin disruption, mice develop an 
extreme double-muscled phenotype with dramatic increases in muscle weights and 
myofiber size due to muscle hypertrophy and hyperplasia. [90] Upon further investigation, 
it was determined that myostatin signaling occurs through the activin type II receptors, 
with activin receptor type IIB (ACVR2B) having a much greater affinity for myostatin 
than activin receptor type IIA (ACVR2A). [91, 92] This finding has led many 
investigators, including those in the pharmaceutical industry, to develop soluble decoy 
activin type II receptors to sequester myostatin and promote muscle growth in patients 





Because the myostatin and activin ligands exert such profound effects in skeletal 
muscle, we and others have begun to explore the hypothesis that activins might also 
regulate growth and development of adjacent bone tissue.  Activins are first seen in the 
developing skeleton in prechondrogenic limb condensations and then during 
chondrogenesis. [97-99] The primary activin ligand, Activin A, is a dimer of two activin 
Figure 1.2: Myostatin and Activin Signaling in Skeletal Muscle  
Myostatin and activin ligands bind to the activin type II receptors to transduce 
signaling through receptor-Smads to inhibit muscle development. [84]   
Note: Reproduced with permission from “Treating cancer cachexia to treat cancer” by 




βA subunits and is present in proliferating chondrocytes, indicating that activins are 
important signaling molecules during chondrogenesis and skeletal development. [100] 
Studies using transgenic mice have also suggested that activins play a critical role in 
skeletal formation.  Activin βA global null mice are born with cleft palates and without 
incisors. [101, 102] Likewise, activin receptor type IIA (ACVR2A) deficient mice 
exhibited mandibular hypoplasia as well as other facial and skeletal abnormalities 
resembling the characteristics of Pierre-Robinson syndrome in humans. [101] Similar to 
BMPs, activin signaling also plays a significant role in axial patterning during 
embryogenesis.  Activin receptor type IIA and IIB are involved in mediating the 
spatiotemporal expression of multiple Hox genes in the anterior-posterior axis. [103] 
While it is clear that activin receptor signaling is important in skeletal development and 
homeostasis, the exact effects of activin signaling, whether stimulatory or inhibitory, has 
had some controversy.  
 Reports by several groups have suggested that activins act in a stimulatory role 
during osteoblastogenesis. [104-106] Likewise, other in vivo data has also indicated that 
activin administration was stimulatory in nature, as local injection of activin A improved 
fibula fracture and calvarial defect healing in rats. [107, 108] However, more recent 
evidence using osteoblast cultures and bone marrow stromal cells has suggested that 
activins are in fact inhibitory in nature. [109, 110] Eijken et al recently demonstrated that 
administration of activin ligands to human osteoblast cultures significantly inhibited their 
ability to mineralize the surrounding collagen matrix.  The investigators further proposed 
that the inhibitory effect is primarily an autocrine mechanism mediated by locally 
17 
produced osteoblast-derived activin ligands.  To confirm this assertion, the investigators 
administered recombinant follistatin, a natural activin antagonist, to osteoblast cultures 
and demonstrated enhanced matrix mineralization, further supporting an inhibitory role 
for activins. [109] In addition to these results, systemic inhibition of activin ligands using 
pharmacological approaches has proven to have a significant anabolic effect in bone. 
Lotinun et al demonstrated that soluble activin receptor administration resulted in a near 
doubling of the bone volume and the bone formation rate in the distal femur of 
Cynomolgus monkeys.  Additionally, systemic activin ligand suppression also reduced 
osteoclast numbers and osteoclast surfaces.  Similar anabolic bone changes were also 
evident in the femoral neck and thoracic vertebrae of treated primates. [111-113] 
However, it remains unclear if the increases in bone volume are the result of increased 
mechanical forces secondary to muscle hypertrophy or are a primary effect on bone 
homeostasis.  Because of these discordant observations, more investigation is necessary 
to better understand the exact effects that activins exert on skeletal tissues. 
 
1.7 Targeting Activin Signaling in Muscle 
and Bone Injuries 
Previous studies have demonstrated that systemic activin inhibition induces 
anabolic changes in both bone and muscle.  These results strongly support the rationale 
for their use in settings of complex injuries involving muscle and bone. Multi-tissue 
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injuries are some of the most challenging cases that orthopaedic surgeons face and often 
result in poor outcomes.  One of the primary contributors to these subpar results is the 
lack of treatment options.  Furthermore, treatment modalities are often viewed as two 
individual components – one for muscle injury and another for the underlying bone 
defect.  However, these two tissues do not exist as two separate entities but rather are 
intimately related in form, function, and regeneration.  It is well known that fractures 
with surrounding soft tissue damage have much higher complication rates. [114] 
Additionally, clinical evidence demonstrates that overlying muscle flap transplantation 
significantly improves fracture healing and union rates. [115-118] This synergy between 
muscle and bone during development and repair further strengthens a holistic treatment 
approach to composite musculoskeletal injuries. 
While much is known about the fracture repair process, understanding the 
surrounding injury environment including the precise muscle-bone interactions during 
composite injury healing is critical to developing new treatment strategies.  In a 
composite injury, the surrounding musculature is a source of vascular supply to provide 
nutrients to the underlying bone.  However, emerging research has shown that the 
adjacent muscle may also provide osteoprogenitors to aid in fracture healing, particularly 
when the periosteum is insufficient for bone healing. [119]  
 The importance of revascularization in muscle and bone regeneration is well-
documented.  Following typical long bone fracture, angiogenesis precedes osteogenesis 
and is required for successful endochondral ossification. [120-123] The surrounding 
musculature has been proposed as a source of angiogenic signals and cells that provide 
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the underlying fracture with oxygen, nutrients, and osteoprogenitors. [124, 125] 
Migrating progenitors cells such mesenchymal stem cells and pericytes are delivered to 
the fracture site via this newly formed vascular network.  The importance of the 
overlying muscle and neovascularization to fracture healing is also well established 
clinically.  Non-union is four times more likely in fractures with impaired vascular 
function. [126] Additionally, muscle flap coverage during composite musculoskeletal 
injuries has been shown to improve callus vascularization and rates of bony union as 
compared to skin closure, further emphasizing the role of adjacent muscle to bone healing. 
[127-130] In several different fracture models, fracture calluses tend to be the largest and 
densest at the site of bone and muscle interfaces, which suggests that the adjacent muscle 
is strong regulator of callus formation. [131]  
 Composite musculoskeletal injuries are particularly difficult to manage, as 
damage to one tissue severely impairs the healing of the other.  In this regard, 
therapeutics that target both bone and muscle tissues simultaneously would represent an 
ideal treatment modality.  As discussed above, systemic soluble activin receptor 
administration has been shown to increase muscle and bone mass simultaneously, which 
would be an ideal treatment approach in composite injuries.  As such, we conducted a 
comprehensive series of studies to explore the use of activin-targeted biologics for the 
treatment of composite musculoskeletal injuries.  
 In summary, the aims of this dissertation are to better understand the role of 
activin signaling in skeletal tissues and investigate its therapeutic potential in composite 
muscle and bone injuries.  Using pharmacological and genetic approaches, the studies 
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2 Activin Receptor Type II A (ACVR2A) 
Functions Directly in Osteoblasts as a Negative 
Regulator of Bone Mass  
2.1 Abstract 
Bone and skeletal muscle mass are highly correlated in mammals, suggesting the 
existence of common anabolic signaling networks that coordinate the development of 
these two anatomically adjacent tissues.  The activin signaling pathway is an attractive 
candidate to fulfill such a role.  In the present study, we generated mice with conditional 
deletion of ACVR2A, ACVR2B, or both, specifically in osteoblasts, to determine the 
contribution of activin receptor signaling in regulating bone mass.  
Immunohistochemistry localized ACVR2A and ACVR2B to osteoblasts and osteocytes 
in bone.  Primary osteoblasts expressed activin signaling components, including 
ACVR2A, ACVR2B, and ACVR1B (ALK4) and demonstrated increased levels of 
phosphorylated Smad2/3 upon exposure to activin ligands.  In vitro, osteoblasts lacking 
ACVR2B did not show significant changes. However, osteoblasts deficient in ACVR2A 
exhibited enhanced differentiation by alkaline phosphatase activity, mineral deposition, 
and transcriptional expression of Osterix, Osteocalcin, and Dmp1.  To investigate activin 
signaling in osteoblasts in vivo, we analyzed the skeletal phenotypes of mice lacking 
these receptors in osteoblasts and osteocytes (Osteocalcin-Cre).  Similar to the lack of 
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effect in vitro, ACVR2B deficient mice demonstrated no significant change in any bone 
parameter.  By contrast, mice lacking ACVR2A had significantly increased femoral 
trabecular bone volume at six weeks of age.  Further, compound mutant mice lacking 
both ACVR2A and ACVR2B demonstrated sustained increases in trabecular bone 
volume, similar to ACVR2A single mutants, at six and twelve weeks of age.  Taken 
together, these data indicate that activin signaling, predominantly through ACVR2A, 
functions directly in osteoblasts as a negative regulator of bone mass. 
 
2.2 Significance 
Bone and skeletal muscle mass are highly correlated throughout mammalian 
growth and involution, suggesting the existence of common anabolic pathways that 
synchronize the development and maintenance of these two tissues.  Evidence presented 
in this study suggests the activin signaling pathway is a likely candidate to fulfill such a 
role.  The profound effects of this pathway, predominantly through myostatin and 
ACVR2B, are well established in regulating skeletal muscle mass.  Utilizing genetic 
mouse models, we demonstrate analogous negative regulatory function of the activin 
signaling pathway in osteoblasts, predominantly through activin ligands and ACVR2A, to 





The musculoskeletal system evolved in mammals to perform diverse functions 
that include locomotion, breathing, protecting internal organs, and coordinating global 
energy expenditure.  After the third decade of life, muscles and bones begin to lose their 
mass, leading to unfavorable alterations in their function.  Aging is universally 
accompanied by the loss of bone (osteopenia) and skeletal muscle (sarcopenia), which 
together constitute important global medical problems.  Sarcopenia results in reduced 
walking speed, poor balance, and instability that together predispose to falls and fractures.  
Thus, the coexistence of osteoporosis and sarcopenia severely compounds the problem of 
frailty in the elderly population [132]. 
During organogenesis, muscle and bone develop in close association from 
common mesodermal precursors and accumulate their final adult mass according to 
specific genetic instructions and environmental cues.  Bone forms in a discrete stepwise 
process: mesenchymal precursors, derived from the mesoderm, first migrate to the future 
sites of bone where they condense.  Following condensation, these precursors 
differentiate into chondrocytes or osteoblasts to form cartilage or bone, respectively, 
depending upon positional cues [133].  Once formed, the skeleton is continually 
remodeled throughout life.  These processes of modeling and remodeling are achieved by 
the actions of osteoblasts and osteoclasts, and are coordinated through the actions of 
many autocrine/paracrine factors including Wnts, Hedgehogs, Notch, bone 
morphogenetic protein (BMP) family members, transforming growth factor-β (TGF-β) 
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family members, insulin-like growth factor-1 (IGF-1), fibroblast growth factor-2 (FGF-2), 
and interleukin-6 (IL-6), among others [134].  This developing skeleton becomes encased 
in muscle tissue, which matures along with the adjacent modeling skeleton [135-137].  
Similar to the regulation of bone development and maintenance of mass, skeletal muscle 
development and maintenance is regulated by morphogens and growth factors, many of 
which overlap with those involved in skeletogenesis, such as FGFs, IGF-1 and TGF-β 
[138].  
Among the most important factors controlling muscle development is the 
activin/myostatin family of molecules.  Activin, and closely related inhibin, are members 
of the TGF-β superfamily of molecules [139-141] first discovered over 70 years ago [88, 
139, 141-144].  Like other TGF-β family members, activin and inhibin are produced as 
large precursors containing a signaling domain, a propeptide and a mature C-terminal 
segment that possesses biological activity.  Following cleavage of the propeptide, the 
structure of functional activin and inhibin is a disulfide linked C-terminal dimer.  In the 
case of activin, this dimer consists of two β subunits and for inhibin, one α and one β 
subunit which are encoded by distinct genes [139].  Myostatin (previously GDF-8) was 
discovered subsequently in a screen for novel TGF-β family members [90].  Although 
structurally similar to other TGF-β family members, its expression is restricted almost 
entirely to skeletal muscle, where it functions as a negative regulator of muscle growth 
[90].  All three of these molecules function through serine/threonine kinase activin 
receptors that resemble other TGF-β family receptors.  Type II receptors are responsible 
for ligand binding, which can be tempered by soluble endogenous inhibitors (e.g. 
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follistatin), and type I receptors mediate signal transduction [145-149]. Tissue specificity 
and activity is regulated at multiple levels in the system, including the spatiotemporal 
expression patterns of various components and distinct combinations of receptor/ligand 
binding.  
Myostatin negatively regulates skeletal muscle development by activating 
ACVR2B and initiating Smad2/3 signaling.  Smad2/3 can then activate the MAPK 
pathway to inhibit proliferation through the p21/Rb cascade [150, 151], or directly affect 
MyoD by sequestering it in the nucleus, thus halting differentiation [152].  The 
importance of the myostatin/activin superfamily in skeletal muscle development is 
dramatically illustrated by the grotesque “double muscled” phenotype seen in myostatin 
null animals [90] or in mice carrying global mutations in Acvr2a and Acvr2b [91].  These 
receptors appear to serve redundant functions in skeletal muscle, as heterozygous loss of 
Acvr2b in combination with homozygous loss of Acvr2a results in further increases in 
muscle mass.  Additional studies using pharmacologic approaches to block access of 
myostatin to its receptor also support the importance of this pathway in regulating muscle 
development and size [91, 153-155].  In each of these genetic and pharmacologic models, 
the anabolic effects on muscle are achieved by inhibition of the inhibitory effect of 
myostatin on myoblast proliferation [150, 151] and terminal differentiation [152].   
Mice and humans that develop large muscles also form large, dense bones, and 
the maintenance of bone and muscle mass is tightly coupled in both healthy [156-158] 
and disease states [159].  Conversely, reduced bone mass is commonly associated with a 
number of myopathies including Pompe disease [160], multiple sclerosis [161], spinal 
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muscular atrophy [162].  These observations suggest the possibility that common 
signaling networks control both skeletal muscle and bone development and perhaps 
enable these adjacent tissues to develop in synchrony.  Previous studies have shown 
indirect evidence that the effects of activin receptor signaling are shared within the 
musculoskeletal system and may also affect bone mass.  In support of this notion, 
myostatin deficient mice not only exhibit dramatic increases in muscle mass but also 
significant increases in bone volume [163-166].  Additionally, activin/myostatin decoy 
receptor administration has been shown to cause anabolic changes in both the muscle and 
bone compartments [112, 167, 168].  Recent studies also suggest that the increases in 
bone volume after decoy receptor treatment are a direct effect and independent from 
muscle changes [169].  Moreover, the anabolic effects of activin signaling blockade on 
the skeleton do not appear to be mediated by myostatin.  Treatment with a myostatin-
specific neutralizing antibody did not yield significant bone changes despite drastic 
increases in muscle mass [170].  Additionally, decoy receptor administration in myostatin 
null mice demonstrated significant increases in bone volume without dramatic increases 
in muscle mass [170].  
Taken together, studies to date unequivocally show that inhibition of activin or 
myostatin signaling in skeletal muscle, either by genetic or pharmacological means, 
increases both muscle and bone mass.  However, whether the bone anabolic effects seen 
in these models is due to direct actions on osteoblasts or, alternatively, results indirectly 
through changes brought about by increased muscle mass remains unclear.  It is this 
question that we aimed to investigate in the current study. 
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2.4 Results 
2.4.1 Soluble Activin Type II Receptors Increase 
Bone Mass in vivo and Osteoblast 
Differentiation in vitro 
To begin to investigate the role of activin receptor signaling within the 
musculoskeletal system, we first determined the effects of systemic inhibition of activin 
ligands through intraperitoneal injections of ACVR2A/Fc and ACVR2B/Fc. Consistent 
with previous reports, after just four weeks of soluble activin receptor treatment, there 
were significant increases in all wet muscle weights in both receptor treatment groups 
(Figure 2.1A).  ACVR2A/Fc treated mice showed approximately double the bone volume 
fraction and approximately 25% increase in cortical thickness (Figure 2.1B).  
ACVR2B/Fc treated mice nearly tripled trabecular bone volume, with no significant 
changes in cortical thickness (Figure 2.1C).  To begin to tease out whether these skeletal 
anabolic effects were direct or resulted through increased muscle force or due to release 
of excess humoral factors following the increase in muscle mass, we also examined 
calvarial bone volume, a skeletal site that is both non-load bearing and relatively isolated 
from surrounding musculature.  Calvarial bone volume was significantly increased 
following both ACVR2A/Fc and ACVR2B/Fc treatment (Figure 2.1D).  To further 
demonstrate that soluble activin receptors affect osteoblasts directly, we then performed 
in vitro studies in primary osteoblasts using ACVR2B/Fc to exploit its broad binding 
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affinity for activin ligands.  Here, ACVR2B/Fc administration reduced basal levels of 
phosphorylated SMAD2 (Figure 2.1E).  Furthermore, ACVR2B/Fc (50 ng/mL) treated 
osteoblasts demonstrated modest yet consistent increases in alkaline phosphatase and 
alizarin red staining (Figure 2.1F).  Taken together, these experiments strongly suggest 
that the anabolic effects of activin receptor signaling blockade observed in the skeleton 




Figure 2.1: Soluble Activin Receptor Administration Increases Bone Volume in 
vivo and Enhances Osteoblast Differentiation in vitro 
ACVR2A/Fc and ACVR2B/Fc treatment demonstrates significant increases in skeletal 
muscle weights as compared to vehicle treated controls (A). ACVR2A/Fc 
administration exhibits a near doubling in trabecular bone volume/tissue volume and a 
significant increase in cortical thickness (B). Similarly, ACVR2B/Fc treatment 
demonstrates a near tripling in trabecular bone volume/tissue volume but no 
significant increase in cortical thickness (C). Both ACVR2A/Fc and ACVR2B/Fc 
treatment demonstrate significant increases in calvarial bone volume (D). 
ACVR2B/Fc treatment shows a dose-dependent reduction of Smad2 phosphorylation 
in vitro (E). Further in vitro analysis demonstrates that ACVR2B/Fc treatment 
enhances alkaline phosphatase activity and mineral deposition by alizarin red staining 
in osteoblast differentiation cultures (F). 
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2.4.2 Activin Receptor Signaling Components Are 
Expressed and Functional in Osteoblasts 
We next surveyed the transcriptional expression of the components of activin 
receptor signaling in differentiated osteoblast cultures and compared these results to 
skeletal muscle, a tissue in which the function of this pathway is well established.  
Activin type II receptors were expressed in differentiated osteoblasts, with ACVR2A 
expression at levels equal to skeletal muscle and ACVR2B at significantly lower, near 
negligible, levels in osteoblasts as compared to muscle.  The cognate type I receptor to 
the activin type II receptors (ACVR1B/ALK4) and the monomeric components of activin 
ligands (InhBA and InhBB) were also highly expressed in differentiated osteoblasts 
(Figure 2.2A).  Further supporting the notion that activin signaling is important for 
osteoblast function, the expression of activin receptors also increased throughout the 
course of osteoblast differentiation, particularly for ACVR2A (Figure 2.2B).  It should 
also be noted that, despite the two-fold increase in ACVR2B during osteoblast 
differentiation, its expression remained orders of magnitude lower than ACVR2A.  
Expression of ACVR2A (Figure 2.2C) and ACVR2B (Figure 2.3A) was also evident in 
vivo and localized to osteoblasts and osteocytes within the cortical and trabecular bone by 
immunohistochemistry.  Finally, functionality of activin receptor signaling in osteoblasts 
was demonstrated in vitro by phosphorylation of Smad2 following activin ligand (Activin 
A, AB, or B) treatment (Figure 2.2D).  These experiments indicate that the activin type II 
receptors, predominantly ACVR2A, are expressed and functional within the osteoblast in 







Figure 2.2: Activin Receptor Signaling Components Are Expressed and 
Functional in Osteoblasts 
Transcriptional expression assays demonstrate that the activin signaling components 
are expressed in primary osteoblasts as compared to skeletal muscle (A). ACVR2A 
and ACVR2B increase transcriptional expression with osteoblast differentiation (B). 
Immunohistochemistry localizes ACVR2A (white arrowheads) to osteoblasts and 
osteocytes in bone sections (C). Phosphorylation of Smad2 following activin ligand 




Figure 2.3: Disruption of ACVR2B Does Not Affect Osteoblast Differentiation in 
vitro 
ACVR2B was localized to osteoblasts and osteocytes by immunohistochemistry (A). 
However, disruption of ACVR2B did not affect osteoblast differentiation as shown by 









2.4.3 Disruption of ACVR2A Enhances Osteoblast 
Differentiation in vitro 
To next determine the role of activin receptor signaling in osteoblast function, we 
differentiated primary calvarial osteoblasts from either ACVR2A or ACVR2B floxed 
neonates and deleted the receptors using an adenoviral vector expressing the Cre 
recombinase.  Proliferation, as assessed by BrdU incorporation, demonstrated a slight 
decrease in ΔACVR2A osteoblasts (Figure 2.4A) while ΔACVR2B osteoblasts 
demonstrated no significant change (Figure 2.4B).  ΔACVR2B osteoblasts were 
unaffected in other functional assays as well, demonstrating no difference in alkaline 
phosphatase activity (Figure 2.3B) or mineral deposition (Figure 2.3C).  However, 
differentiated osteoblasts lacking ACVR2A did show dramatic increases in alkaline 
phosphatase staining (Figure 2.4C) as well as enhanced matrix mineralization by alizarin 
red staining (Figure 2.4D).  In accord with these functional assays, transcriptional 
expression of osteoblast markers such as Osterix, Osteocalcin, and DMP1 were 
significantly upregulated at Day 7 in ΔACVR2A osteoblasts (Figure 2.4E).  Together, 
these data demonstrate that disruption of ACVR2A enhances osteoblast differentiation 
and maturation in vitro. 
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Figure 2.4: Disruption of ACVR2A Enhances Osteoblast Differentiation in vitro 
∆ACVR2A osteoblasts exhibit a slight decrease in proliferation (A) while disruption 
of ACVR2B does not alter osteoblast proliferation (B). Osteoblast differentiation is 
significantly enhanced with ACVR2A disruption as shown by increased alkaline 
phosphatase activity (C) and mineral deposition (D). Disruption of ACVR2A induces 
increased transcriptional expression of osteoblast differentiation markers such as 
Osterix, Osteocalcin, and Dmp1 at Day 7 (E). 
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2.4.4 ΔACVR2A Mice Demonstrate Increased Bone 
Volume  
To determine the consequence of osteoblast-specific disruption of ACVR2A in 
vivo, mice lacking ACVR2A within the osteoblast lineage were generated by crosses of 
Oc-Cre-Tg+; ACVR2Aflox/flox with ACVR2Aflox/flox mice.  Transgenic ACVR2Aflox/flox 
mice carrying Oc-Cre+ (ΔACVR2A) were born within the expected Mendelian ratios and 
had normal lifespans.  Allele-specific PCR was performed to confirm that recombination 
occurred only within skeletal tissues (Figure 2.5A).  MicroCT analysis of the distal femur 
revealed that ΔACVR2A male mice at six weeks of age exhibited increased trabecular 
bone volume/tissue volume (BV/TV) (34.2 ± 4.1%) and trabecular number (24.1 ± 1.9%).  
Furthermore, twelve-week-old male ΔACVR2A mice demonstrated sustained increases 
in femoral trabecular bone volume fraction (47.9 ± 5.4%), trabecular thickness (13.3 ± 
0.7%), trabecular number (27.8 ± 1.7%), and decreases in trabecular spacing (-6.2 ± 
0.1%) (Figure 2.6A-D).  Cortical parameters within these males were not significantly 
changed at six weeks of age.  However, at twelve weeks of age, the ΔACVR2A male 
mice demonstrated increases in tissue area (13.0 ± 0.4%), bone area (15.9 ± 0.7%), polar 
moment of inertia (31.6 ± 0.3%), and cortical thickness (8.6 ± 0.3%) (Figure 2.6E-H).  
Similar changes, albeit of lesser magnitude, were observed in female mice at six and 
twelve weeks of age (data not shown).  Histomorphometric analysis of the contralateral 
distal femur from male mice confirmed the increase in trabecular bone volume in 
ΔACVR2A mice at six and twelve weeks of age (Table 1).  Surprisingly, there were no 
significant changes in osteoblast or osteoclast numbers, nor dynamic parameters, 
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suggesting the cellular changes that lead to increased bone volume in ΔACVR2A mice 
likely occurred much earlier in development.  Overall, these findings demonstrate that 








Figure 2.5: Allele-Specific PCR Confirms Cre-Lox Recombination Occurs 
Exclusively in Skeletal Tissues 
Osteocalcin-directed Cre-Lox recombination of ACVR2A (A) and ACVR2B (B) 
occurs exclusively in skeletal tissues. Allele-specific PCR results of femur and 






Figure 2.6: Femurs of ∆ACVR2A Male Mice Exhibit Increased Bone Volume 
Femurs from ∆ACVR2A mice exhibit increases in trabecular bone parameters (A-D), 
including bone volume/tissue volume (A) and trabecular number (D) at six weeks of 
age. Femurs of ∆ACVR2A mice at twelve weeks of age demonstrate increases in 
trabecular bone volume/tissue volume (A), trabecular thickness (B), trabecular number 
(C), and a decrease in trabecular spacing (D). Femoral cortical parameters (E-H) were 
unchanged at six weeks of age in ∆ACVR2A mice. However, cortical tissue area (E), 
bone area (F), and cross-sectional thickness (H) were increased while cortical bone 
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BV/TV 5.09 ± 0.28 6.28 ± 0.57* 7.87 ± 0.57 9.99 ± 0.77*
Tb.Th 18.56 ± 0.48 20.88 ± 1.14 22.83 ± 0.90 25.70 ± 1.14*
Tb.Sp 356.18 ± 22.68 323.32 ± 19.59 275.55 ± 16.18 239.75 ± 14.45*
OV/BV 0.99 ± 0.23 0.86 ± 0.07 0.33 ± 0.05 0.51 ± 0.07*
OS/BS 4.17 ± 0.74 3.48 ± 0.27 2.54 ± 0.42 3.18 ± 0.38
O.Th 2.28 ± 0.25 2.53 ± 0.19 1.60 ± 0.15 2.06 ± 0.09*
N.Ob/BS 254.44 ± 39.35 237.30 ± 79.45 144.80 ± 39.62 170.88 ± 65.61
Ob.S/BS 3.68 ± 0.51 2.98 ± 0.90 2.11 ± 0.60 2.44 ± 1.07
ES/BS 2.96 ± 0.61 3.18 ± 0.52 2.15 ± 0.42 2.83 ± 0.62
E.De 5.52 ± 0.46 4.23 ± 0.27* 3.95 ± 0.64 4.15 ± 0.36
N.Oc/BS 95.43 ± 16.49 112.08 ± 19.95 75.73 ± 14.79 93.24 ± 20.41
Oc.S/BS 2.83 ± 0.64 3.00 ± 0.53 2.13 ± 0.42 2.74 ± 0.61
MAR 2.04 ± 0.13 1.71 ± 0.06* 1.13 ± 0.07 1.11 ± 0.07
dLS/BS 9.77 ± 0.83 10.07 ± 1.17 10.65 ± 0.95 12.60 ± 1.68
sLS/BS 7.18 ± 0.61 8.70 ± 1.27 5.97 ± 0.34 5.55 ± 0.66
MS/BS 13.36 ± 0.96 14.42 ± 1.44 13.64 ± 1.07 15.37 ± 1.83
BFR/BS 3.85 ± 0.37 3.41 ± 0.30 3.21 ± 0.35 3.43 ± 0.46
Omt 1.17 ± 0.15 1.47 ± 0.08* 1.47 ± 0.16 1.90 ± 0.13*





Histomorphometry was performed in trabecular bone of the distal femur. BV/TV: Bone Volume/Tissue Volume (%); Tb.Th: 
Trabecular Thickness (mm); Tb.Sp: Trabecular Separation (mm); OV/BV: Osteoid Volume/Bone Volume (%); OS/BS: 
Osteoid Surface/Bone Surface (%); O.Th: Osteoid Thickness (mm); N.Ob/BS: Osteoblast Number/Bone Surface (no./
100mm); Ob.S/BS: Osteoblast Surface/Bone Surface (%); ES/BS: Erosion Surface/Bone Surface (%); E.De: Erosion Depth 
(mm); N.Oc/BS: Osteoclast Number/Bone Surface (no./100mm); Oc.S/BS: Osteoclast Surface/Bone Surface (%); MAR: 
Mineral Apposition Rate (day); dLS/BS: Double Labeled Surface/Bone Surface (%); sLS/BS: Single Labeled Surface/Bone 
Surface (%); MS/BS: Mineralizing Surface/Bone Surface (%); BFR/BS: Bone Formation Rate/Bone Surface (µm³/µm²/d); 
Omt: Osteoid Maturation Time (day); Mlt: Mineralization Lag Time (day). Values shown are mean±S.E.M. P<0.05 vs. age-
matched control
Table 1 Bone Histomorphometry 
Table 1: Bone Histomorphometry 
Histomorphometry was perf rmed in trabecular bone of the distal femur in 
ΔACVR2A male mice. BV/TV: Bone Volume/Tissue Volume (%); Tb.Th: Trabecular 
Thickness (mm); Tb.Sp: Trabecular Spacing (mm); OV/BV: Osteoid Volume/Bone 
Volume (%); OS/BS: Osteoid Surface/Bone Surface (%); O.Th: Osteoid Thickness 
(mm); N.Ob/BS: Osteoblast Number/Bone Surface (no./100mm); Ob.S/BS: Osteoblast 
Surface/Bone Surface (%); ES/BS: Erosion Surface/Bone Surface (%); E.De: Erosion 
Depth (mm); N.Oc/BS: Osteoclast Number/Bone Surface (no./100mm); Oc.S/BS: 
Osteoclast Surface/Bone Surface (%); MAR: Mineral Apposition Rate (day); dLS/BS: 
Double Labeled Surface/Bone Surface (%); sLS/BS: Single Labeled Surface/Bone 
Surface (%); MS/BS: Mineralizing Surface/Bone Surface (%); BFR/BS: Bone 
Formation Rate/Bone Surface (µm3/µm2/day); Omt: Osteoid Maturation Time (day); 
Mlt: Mineralization Lag Time (day). Values shown are mean ± S.E.M. *P<0.05 vs. 
age-matched control 
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2.4.5 ΔACVR2B Mice Exhibit No Skeletal Changes 
Despite exhibiting no effect on osteoblasts in vitro, we further explored whether 
ACVR2B may behave differently in vivo, as it was identified in osteoblasts by 
immunohistochemistry.  We disrupted ACVR2B in the osteoblast lineage using the same 
osteocalcin-driven Cre by crossing Oc-Cre-Tg+; ACVR2Bflox/flox with ACVR2Bflox/flox 
mice.  Transgenic ACVR2Bflox/flox mice carrying Oc-Cre+ (ΔACVR2B) were born within 
the expected Mendelian ratios and with normal lifespans.  Allele-specific PCR was 
performed to confirm that recombination occurred only within skeletal tissues (Figure 
2.5B).  Micro CT analysis of the distal femur of ΔACVR2B mice showed virtually no 
changes at six and twelve weeks of age (Figure 2.7 – males, female data not shown), 
suggesting that ACVR2B does not function as the primary receptor for activin signaling 







Figure 2.7: ACVR2B Disruption Does Not Affect Bone Volume in vivo 
Femurs of ΔACVR2B male mice show no significant changes in trabecular (A-D) or 
cortical bone parameters (E-H) at six or twelve weeks of age. Trabecular bone 
parameters include bone volume/tissue volume (A), trabecular thickness (B), 
trabecular number (C), and trabecular spacing (D). Apart from a slight reduction in 
bone area/tissue area at 6 weeks of age (G), there are no significant changes observed 
in cortical parameters, including tissue area (E), bone area (F), bone area/tissue area 
(G), and cross-sectional thickness (H) in six or twelve-week-old ΔACVR2B male 
mice. 
ACVR2BControl
A) B) C) D)
E) F) G) H)
Supplemental Figure 3
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2.4.6 Compound ΔACVR2A/2B Mice Exhibit a 
Phenotype Similar to ΔACVR2A Mice 
To unequivocally determine if ACVR2B is able to function in osteoblasts in vivo 
– specifically, to partially compensate for the loss of ACVR2A – we generated compound 
mutants of ACVR2A and ACVR2B (ΔACVR2A/2B) in the osteoblast lineage by 
crossing Oc-Cre-Tg+; ACVR2A/2Bflox/flox with ACVR2A/2Bflox/flox mice.  ΔACVR2A/2B 
male mice showed significant increases in trabecular bone volume fraction (22.6 ± 1.1%), 
trabecular number (25.0 ± 3.9%), and decreased trabecular spacing (-15.1 ± 3.6%) at six 
weeks of age.  At twelve weeks of age, ΔACVR2A/2B male mice demonstrated sustained 
increases in trabecular bone volume fraction (24.8 ± 2.2%) and trabecular number (18.4 ± 
6.0%) (Figure 2.8A-D).  However, unlike ΔACVR2A mice, the ΔACVR2A/2B mice 
demonstrated no significant changes in cortical parameters at twelve weeks of age 
(Figure 2.8E-H).  As was the case for ΔACVR2A mice, female ΔACVR2A/2B mice 
displayed skeletal changes similar to males with slightly lesser magnitude (not shown).  
These data demonstrate that compound ΔACVR2A/2B mutant mice have increases in 
trabecular bone parameters similar to ΔACVR2A mutants, further supporting the notion 

























































































































































A) B) C) D)
E) F) G) H)
Figure 2.8: Femurs of ∆ACVR2A/2B Mice Exhibit Similar Changes in Bone 
Volume as ∆ACVR2A Mice 
Femurs of ∆ACVR2A/2B male mice exhibit similar increases in trabecular bone 
parameters (A-D) as ∆ACVR2A mice. ∆ACVR2A/2B mice demonstrate increases in 
trabecular bone volume/tissue volume (A), trabecular number (C), and a decrease in 
trabecular spacing (D) at six weeks of ago. These increases were sustained in 
trabecular bone volume/tissue volume (A) and trabecular number (C) at twelve weeks 
of age. However, no significant changes were seen in trabecular thickness (B) at six or 
twelve weeks of age. Cortical bone parameters, including tissue area (E), bone area 
(F), bone area/tissue area (G), and cross-sectional thickness (H), were unchanged in 
six and twelve-week-old ∆ACVR2A/2B male mice. 
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2.4.7 Skeletal Changes in ΔACVR2A Mice Are 
Accompanied by Increased Mechanical 
Attributes 
An important consideration for future therapeutic targeting of this pathway in 
bone is whether the additional bone mass observed in the mutant mice is mechanically 
competent.  Thus, we also evaluated changes in mechanical properties of femurs from 
ΔACVR2A male mice by three-point bending.  ΔACVR2A mutants demonstrated 
significant increases in ultimate moment (24.8 ± 2.0%) and bending rigidity (30 ± 2.7%) 
with non-significant trends in ultimate stress (10.1 ± 0.5%).  In addition, pre-yield 
parameters including strain (21.3 ± 1.6%), energy (45.8 ± 6.3%), and toughness (36.1 ± 
4.0%) were also significantly increased compared to controls (Figure 2.9A-G).  The 
ultimate bending energy and Young’s modulus were, however, unchanged (Figure 2.9D 
and 2.9H, respectively).  Overall, the mechanical testing indicates that the additional bone 
produced in mice with osteoblast-specific disruption of ACVR2A is of high mechanical 

























































































































































































A) B) C) D)
E) F) G) H)
Control ACVR2A
Figure 2.9: Skeletal Changes in ΔACVR2A Mice Are Accompanied by Increased 
Mechanical Properties 
Three-point bending analysis of femurs from ΔACVR2A mice demonstrates 
significant increases in mechanical properties, such as the ultimate moment (A), 
bending rigidity (B), pre-yield strain (E), pre-yield energy (F), and pre-yield toughness 
(G), and non-significant trends in ultimate stress (C). There were, however, no 
significant changes in the ultimate bending energy (D) or Young’s modulus (H) with 
ACVR2A disruption. 
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2.4.8 Activin Receptor Signaling in Osteoblasts 
Contributes Significantly to the Anabolic 
Effects Observed with Soluble Receptor 
Administration  
Finally, we returned to the question of what proportion of the anabolic effect 
observed from soluble activin receptor treatment results from direct effects on the 
osteoblast versus indirect effects from skeletal muscle, or perhaps even other secondary 
systems.  To do so, we treated ΔACVR2A/2B mutant mice with ACVR2B/Fc for four 
weeks, as done in our initial experiments, and compared the percentage change in bone 
volume with that observed in wild type mice treated with the soluble receptor.  In wild 
type animals treated with ACVR2B/Fc, the trabecular bone volume fraction increased by 
114 ± 16.0%.  By contrast, ΔACVR2A/2B mice treated with ACVR2B/Fc gained 62.3 ± 
14.5% in trabecular BV/TV (Figure 2.10A).  Similarly, increases in trabecular number 
were differentially affected between control (82.0 ± 8.5%) and ΔACVR2A/2B (50.1 ± 
11.1%) mice (Figure 2.10C).  In contrast to the changes observed in trabecular bone, 
there were no differential increases in muscle mass (gastrocnemius, tibialis anterior, and 
quadriceps) between control and ΔACVR2A/2B mice with ACVR2B/Fc administration 
(Figure 2.10E-G).  Taken together, these data would suggest that a substantial portion of 
the effect of soluble activin receptor administration on bone volume (>50%) results from 



































































































































Figure 2.10: Activin Receptor Signaling is a Significant Contributor to Anabolic 
Changes Observed with Soluble Receptor Administration 
Soluble activin receptor treatment with ACVR2B/Fc demonstrates attenuated 
increases in bone volume/tissue volume (A), trabecular thickness (B), and trabecular 
number (C) in ∆ACVR2A/2B mice. There were no differential changes in trabecular 
bone spacing (D) or differential increases in skeletal muscle weights, including the 
gastrocnemius (E), tibialis anterior (F), or quadriceps (G) muscles. 
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2.5 Discussion 
We have described, for the first time, a role for activin receptor signaling in 
osteoblasts that is analogous to the known function of this pathway as a negative 
regulator of muscle development and mass.  Curiously, early studies suggested that 
activin A exerted a stimulatory effect on osteoblastogenesis [104, 106], but more recent 
reports using human osteoblast preparations suggest that activin inhibits 
osteoblastogenesis and mineralization [109].  Initial in vivo studies in bone were also 
conflicting.  For example, local injection of activin A into rat fibula fractures [107] or 
over the calvaria of rat neonates [108] increased bone accumulation.  In more recent 
studies, systemic infusion with a soluble ACVR2A resulted in increased bone mass in 
both mice [167] and monkeys [111, 112].  Moreover, administration of soluble ACVR2A 
increased markers of bone formation in humans [113].  Histomorphometric analysis of 
bones from mice and monkeys treated with this ACVR2A fusion peptide demonstrated 
that the anabolic effects were attributable to increased osteoblast activity [112, 167].  Our 
initial studies with soluble activin receptor administration support these previous studies 
of pharmacologic blockade of activin signaling, even over the considerably shorter course 
of treatment we used.  We utilized this 4-week treatment in hopes of minimizing the 
effect of long-term adaptation of bone mass in response to the increased mechanical 
forces that follow the additional muscle mass gained from systemic activin receptor 
blockade.  Combined with the observed increases in bone mass in the calvarium, a 
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skeletal site that is neither load bearing nor encased in skeletal muscle like the femur, we 
were encouraged to further investigate the direct activity of this pathway in osteoblasts. 
Further interrogation of this pathway in osteoblasts – both through pharmacologic 
and genetic blockade of activin receptor activity – demonstrated that activin receptor 
signaling is, indeed, a negative regulator of osteoblast function.  Interestingly, both in 
vitro and in vivo, this effect appears to be nearly entirely dependent on ACVR2A.  
Previous studies have suggested that myostatin and/or ACRV2B may also play a role in 
regulating bone mass.  For example, myostatin null mice have increased bone mass [163], 
and infusion of a soluble ACVR2B fusion molecule increased bone mass in a mouse 
model of androgen deprivation [171].  In our hands, as well, administration of soluble 
ACVR2B resulted in profound increases in trabecular bone volume.  However, we 
consider it unlikely that ACVR2B and myostatin are physiologically relevant in 
osteoblasts to regulate bone mass for the following reasons.  In the case of the myostatin 
null mice, increased bone mass was only observed in the regions of long bones 
immediately adjacent to entheses [163], strongly suggesting that the effect is secondary to 
increased mechanical force generated as a result of the double muscled phenotype in 
myostatin null mice.  Additionally, we observed no detectable expression of myostatin in 
primary mouse osteoblasts, and ACVR2B expression was orders of magnitude lower than 
ACVR2A expression (Figure 2.2A).  Finally, while ACVR2B and various soluble forms 
of this receptor do predominantly bind and sequester myostatin, ACVR2B is the more 
promiscuous of the two activin receptors and also binds activin ligands with nearly as 
high affinity as it binds myostatin [172]. 
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Our studies with genetic disruption of ACVR2A and ACVR2B in osteoblasts bear 
out the notion that ACVR2A functions as a negative regulator of osteoblast function.  
Both in vitro and in vivo, disruption of ACVR2B had no discernable effect on osteoblast 
function.  Moreover, compound mutants that lacked both activin receptors in osteoblasts 
displayed changes in trabecular bone that were strikingly similar to ΔACVR2A mice.  Of 
interest, however, was the fact that the increased cortical bone phenotype observed in 
ΔACVR2A mice at 12 weeks of age (Figure 2.6E-H) was not observed in the double 
ΔACVR2A/2B mice (Figure 2.8E-H).  One possible explanation for this change – which, 
presumably, is exactly the opposite of what one would expect if ACVR2B were able to 
partially compensate for ACVR2A loss – is that complete loss of type II activin receptors 
from osteoblasts alters other TGF-β family and/or BMP signaling in osteoblasts, as these 
receptor families are well known to be promiscuous in ligand binding and signaling 
activity.  In support of this notion, Lowery and colleagues have recently demonstrated 
that selective disruption of BMPR2 in osteoprogenitor cells actually impaired activin 
signaling, with no effect on BMP signaling, resulting in a high bone mass phenotype 
[173].  Their result also indirectly supports our overall finding that activin signaling in 
osteoblasts acts as a negative regulator of their function.  
Despite the clear skeletal phenotype observed in ΔACVR2A mice, we were 
unable to detect any significant changes in bone cell numbers at either time point 
observed, in either sex.  We believe that these changes must have occurred much earlier 
in development for a number of reasons.  Both genetic and pharmacologic blockade of 
activin signaling in vitro resulted in rapid and robust differentiation of osteoblasts.  We 
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presume it is likely that the same effect would have taken place in vivo with an early 
burst of osteoblast differentiation and bone formation that was then damped by yet 
unknown compensatory mechanisms.  In support of this idea, the only statistically 
significant histomorphometric parameters observed were a slightly repressed mineral 
apposition rate at six weeks of age, increased osteoid maturation time at both six and 
twelve weeks of age, and increased mineralization lag time at twelve weeks of age (Table 
1); all opposite of what one would typically expect in mice with higher bone mass, but 
consistent with a repression of osteoblast activity.  Future studies are already underway to 
examine the role of activin receptor signaling at varying points in the osteoblast lineage, 
the current study having focused on the mature osteoblast/osteocyte using a human 
osteocalcin Cre driver, and will explore these early developmental changes in greater 
detail.  Regardless, our current study provides clear evidence of the importance of 
ACVR2A in osteoblasts as a negative regulator of bone development and mass. 
In an attempt to begin to understand the precise contribution of activin receptor 
signaling in osteoblasts to the observed anabolic effects of soluble activin receptor 
administration in the skeleton, we also treated the double ΔACVR2A/2B mice with 
soluble ACVR2B.  The results of this experiment suggest that over half of the observed 
increase in bone mass following administration of soluble ACVR2B/Fc is due to the 
direct activity of this pathway in osteoblasts (Figure 2.10A).  Interestingly, the absolute 
final trabecular bone volume fraction following soluble receptor treatment was nearly the 
same between treated wild type mice and double mutants, suggesting a sort of ceiling by 
which modulating this pathway can influence bone volume in mice (not shown).  
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Interestingly, we observed no difference in skeletal muscle wet weights between 
ACVR2B/Fc treated wild type and ΔACVR2A/2B mice, hinting that changes in activin 
receptor signaling in osteoblasts do not seem to reciprocally affect skeletal muscle.  The 
additional increase in bone volume in ΔACVR2A/2B mice following ACVR2B/Fc 
treatment is likely to occur from multiple secondary mechanisms, given the established 
functions of activin signaling in other systems known to affect bone, e.g. the pituitary and 
immune system [174, 175].  Future studies are already underway to determine the precise 
contribution of skeletal muscle to this effect by observing changes in the skeleton 
following muscle-specific disruption of activin receptor signaling. 
Our study is the first to conclusively demonstrate the activity of activin receptor 
signaling in osteoblasts as a negative regulator of bone development, analogous to the 
well-established function of this pathway in skeletal muscle.  This effect appears to be 
mediated predominantly through ACVR2A and activin ligands, suggesting an 
evolutionary split in the control of musculoskeletal development; with ACVR2A and 
activin ligands controlling the skeleton, while ACVR2B and myostatin exert control over 
skeletal muscle.  Such an arrangement would allow for precise, concerted control of the 
development and maintenance of the musculoskeletal system, and also provides a 




2.6.1 Soluble Activin Type II Receptor Animal 
Studies 
All animal protocols were approved by the Johns Hopkins University Institutional 
Animal Care and Use Committee.  Systemic suppression of activin ligands was 
accomplished by intraperitoneal injections (10 mg/kg BW) of a soluble chimeric fusion 
protein consisting of either the extracellular ACVR2A or ACVR2B domain conjugated to 
the Fc domain of a murine IgG antibody (ACVR2A/Fc or ACVR2B/Fc, respectively). 
Injections were administered weekly for four weeks in twelve-week-old female mice (n = 
5). After soluble activin receptor treatment, skeletal tissues were harvested and wet 
muscle weights were measured.  
 
2.6.2 Transgenic Animal Studies 
Osteoblast-specific disruption of ACVR2A, ACVR2B, or both was accomplished 
by crossing ACVR2Aflox/flox or ACVR2Bflox/flox mice [176], with mice expressing the Cre 
recombinase under the direction of the human osteocalcin promoter (Oc-Cre), in which 
Cre recombinase expression is restricted to mature osteoblasts [177]. Recombination 
53 
within the skeletal tissues was confirmed using allele specific PCR and details are 
available upon request. Control (ACVR2Aflox/flox or ACVR2Bflox/flox) and mutant 
(ACVR2Aflox/flox or ACVR2Bflox/flox; Oc-Cre+) male and female mice were sacrificed at 
six and twelve weeks of age (n = 10). Skeletal tissues then were harvested and fixed in 
formalin overnight and stored until analysis in 70% ethanol. Prior to harvest, six-week-
old mice were double labeled by two sequential intraperitoneal calcein injections (10 
mg/kg BW) at seven and two days prior to sacrifice for dynamic histomorphometric 
analysis. Twelve-week-old mice were double labeled with calcein injections at ten and 
three days before sacrifice. Mice were maintained on a pure C57Bl/6 background. 
 
2.6.3 Microcomputed Tomography (µCT) 
Images of skeletal tissues were obtained using a Skyscan 1172 desktop imaging 
system (Skyscan-Bruker). Scans were performed with an isotropic voxel size of 10 µm at 
65 kV and 200 µA through a 0.5mm aluminum filter. Femoral trabecular parameters were 
measured in a 200 µm region of interest located approximately 50 µm proximal to the 
distal growth plate. Femoral cortical parameters were measured within a 500 µm region 
of interest centered at the midshaft. All bone analysis was performed in accordance with 
the American Society of Bone and Mineral Research (ASBMR) recommended 
parameters [178].  
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2.6.4 Bone Histomorphometry 
For histomorphometric analysis, femurs were fixed in 10% neutral buffered 
formalin, dehydrated, and embedded in polymethylmethacrylate (PMMA). Three-micron 
sections were cut through the primary spongiosium and stained using the Mason-Goldner 
Trichrome stain. Additional serial sections were cut for fluorescent microscopy. 
Osteoblast and osteoclast measures were assessed at standardized sites beneath the 
growth plate using Osteoplan II (Kontron). Static and dynamic parameters were 
calculated in accordance with the ASBMR guidelines [179].  
 
2.6.5 Osteoblast Isolation and Culture 
Osteoblasts were isolated from neonatal calvaria of ACVR2Aflox/flox and 
ACVR2Bflox/flox mice by serial digestion in a 1.8 mg/mL collagenase type I (Worthington 
Biochemical) solution. Calvaria were incubated in 10 mL of collagenase solution at 
37 °C for 15 minutes with constant agitation per digestion cycle. The digestion solutions 
were collected and fresh collagenase was added to the remaining digestion cycles an 
additional four times. Digestions 3-5, containing osteoblasts, were pooled and cultured in 
α-MEM medium containing 10% FBS and 1% penicillin/streptomyocin. Osteoblasts were 
cultured at 37 °C at 5% carbon dioxide in a humidified incubator. Osteoblasts were 
grown to 70% confluency and then transduced in PBS with either a control adenovirus 
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encoding green fluorescent protein (GFP) or an adenovirus encoding Cre recombinase 
(Vector Biolabs) at a titer of 100 MOI. After 1 hour of incubation, osteoblasts were 
supplemented with α-minimum essential medium (α-MEM) containing 10% fetal bovine 
serum and 1% penicillin/streptomyosin and then allowed to recover for 48 hours. 
Osteoblasts were then harvested to assess ACVR2A or ACVR2B deletion efficiency by 
quantitative PCR and re-plated for proliferation studies and differentiation studies. 
 
2.6.6 Osteoblast Proliferation and Differentiation 
Osteoblast proliferation was assessed using BrdU incorporation and flow 
cytometry. Osteoblasts were seeded at a low density of (5 x 104 cells per well) and 
cultured in α-MEM containing 0.5% FBS for 24 hours to arrest cell cycle. BrdU (10 µM) 
(BD Biosciences) was then added to the medium for an additional 24 hours prior to 
harvest to allow incorporation. Osteoblasts were then fixed, stained with anti-BrdU 
antibody and 7-AAD, and analyzed by FACS Calibur flow cytometry (BD Biosciences). 
10,000 events were collected for each sample and the results were processed using 
Flowing Software v. 2.5. For differentiation experiments, control and ΔACVR2A or 
ΔACVR2B osteoblasts were cultured to confluency and then cultured in medium 
supplemented with 10 mM β-glycerol phosphate and 50 µg/mL ascorbic acid. For 
alkaline phosphatase and mineral deposition assays, osteoblasts deficient in activin 
receptor were seeded at confluency and were subsequently differentiated in complete 
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medium supplemented with 10 mM β-glycerol phosphate and 50 µg/mL ascorbic acid. 
Cultures were then fixed at Day 7 and 14 using 100% ethanol and assessed for alkaline 
phosphatase activity and mineral deposition with Fast Red TR/Naphthol AS-MX 
phosphate (Sigma-Aldrich, Corp., St. Louis, MO) or 40 mM Alizarin Red (Sigma) 
staining, respectively. Image analysis was performed using FIJI. [180]  
 
2.6.7 Quantitative Real-Time PCR 
Total RNA was collected from cells and tissue samples using TRIzol (Invitrogen) 
following the manufacturer’s protocol. One microgram of RNA was then reversely 
transcribed using an iScript cDNA synthesis kit (Bio-Rad). Two microliters of cDNA 
were amplified under standard PCR conditions using iQ SYBR Green Supermix (Bio-
rad). All cDNA samples were run in triplicate, averaged, and normalized to endogenous 
β-actin expression levels. Primer sequences were designed using Primer-BLAST (NCBI) 
and are available upon request. 
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2.6.8 Cell Lysis and Immunoblotting  
For signaling experiments, osteoblasts were cultured to near confluence in α-
MEM containing 10% FBS. Cells were then starved in α-MEM containing 0.5% FBS 
overnight to reduce endogenous cellular activity prior to stimulation. Activin A, AB, and 
B (R&D Systems) were added to the medium for a final concentration of 20 ng/mL. 
ACVR2B/Fc was supplemented to a final concentration of 50 ng/mL. Whole cell lysates 
were then collected at appropriate timepoints in lysis buffer (50 mM Tris (pH 7.4), 150 
mM NaCl, 1 mM MgCl2, 1 mM EDTA, 1% Triton X-100 and 10% glycerol). Protein 
concentrations were measured by BCA Protein Assay (Pierce) and 15 µg of total protein 
were loaded into each lane using a mini-SDS-PAGE system (Bio-Rad). Following 
electrophoresis, proteins were transferred to a PDVF membrane using Mini Trans-blot 
Cell System (Bio-Rad). Membranes were then blocked using 5% BSA at room 
temperature for 1 hour and then incubated with antibody of interest (Cell Signaling) at 
4 °C overnight. Protein signal was detected using secondary antibodies conjugated with 
horseradish-peroxidase. Chemiluminescence of bound antibody was produced by 
Supersignal West Femto Substrate (Pierce) and captured by Gel Doc XR+ System (Bio-
Rad). Blot analysis was performed using Image Lab (Bio-Rad).  
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2.6.9 Mechanical Testing 
Femurs were harvested from 12-week-old control and ΔACVR2A male mice. Soft 
tissue was then cleared from the femur and placed on a custom three-point bending 
apparatus with a span of 5.3 mm. After a preload of 0.3 N, the femur was subjected to 
force in displacement control at 0.1 mm/s until fracture was achieved (Bose Electroforce 
3100). Bone hydration was maintained throughout the testing period using PBS. Force-
displacement data and microCT imaging was analyzed using a custom MATLAB 
(MathWorks) program similar to others [181]. 
 
2.6.10 Statistical Analysis 
All values are shown as mean ± standard error of the mean. Statistical 
significance between comparable groups was assessed using Student’s t-test with an 






3 Evaluation of Activin-Targeted Biologics in 
Composite Muscle and Bone Injury 
 
3.1 Introduction 
Composite injuries involving bone and muscle deficits, such as those seen in 
combat veterans, are some of the most challenging cases that orthopedic surgeons 
encounter.  These complex musculoskeletal injuries are difficult to treat clinically and 
often result in compromised function.  One of the primary reasons that these injuries have 
had such poor outcomes is that the treatment approach is oftentimes viewed as two 
individual tissues rather than one functional unit.  However, a more comprehensive 
approach is beginning to take hold with clinicians as they have long observed that muscle 
flap transplantation improves fracture healing and bone union rates.  [182]  
The use of soluble activin receptors is an attractive candidate to address such an 
issue as systemic administration targets both muscle and bone simultaneously.  The dual 
anabolic effect of soluble activin receptor treatment is unique among therapeutic options 




3.2.1 Study Design 
All animal protocols were approved by the Johns Hopkins University Institutional 
Animal Care and Use Committee.  To assess the use of soluble activin receptor 
administration in the setting of composite musculoskeletal injury, a murine model was 
developed consisting of a pinned femoral fracture with an overlying volumetric muscle 
defect.  Soluble activin receptor type IIB (ACVR2B/Fc) was used for these treatment 
studies to take advantage of its broad ligand binding profile as well as its affinity for 
myostatin, since muscle healing was a primary outcome measure.  Vehicle and soluble 
activin receptor mice were treated for eight weeks after surgery and tissues were 
harvested after the administration protocol.  Weekly body weights were recorded and 
intermittent radiographs were taken during the treatment duration. 
 
3.2.2 Composite Musculoskeletal Injury Model 
This model was adapted from previous rodent composite injury models pioneered 
by Drs.  Robert Guldberg and Nick Willett.  [183] Twelve-week old female mice were 
first placed under isoflurane anesthesia (3% induction and 1.5% for maintenance).  The 
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surgical site was assessed by palpation of the left femur and overlying hair was removed 
by surgical clippers and subsequent Nair Hair Removal application.  The site was then 
cleansed and sterilized using Chloraprep wipes (CareFusion).  A skin incision was then 
made along the lateral length of the femur to expose the underlying musculature.  Blunt 
dissection was used to separate the rectus femoris muscle from the biceps femoris muscle 
along the fascial plane to expose the lateral aspect of the femur.  A 5mm biopsy punch 
was then used to create a volumetric muscle defect at the femur midshaft through the 
rectus femoris muscle to the surface of the femur.  A 2 mm longitudinal incision was then 
made to translocate the patellar ligament medially to expose the distal femur head.  Once 
exposed, a 25-gauge needle was inserted just anterior to the intercondylar notch to pilot a 
canal to the femoral marrow cavity.  The needle was then removed and a 12 mm (length) 
X 0.7 mm (diameter) Kirschner wire with a trocar point (Key Surgical) was inserted into 
the marrow cavity.  After wire insertion, a #10 scalpel blade was then used to remove 4 
mm of periosteum with a 2 mm overhang on each side of the proposed osteotomy site.  
After periosteal stripping, 0.22 mm Gigli wire saw was then used to create an osteotomy 
at the femur midshaft.  Once completed, the rectus femoris and biceps femoris muscles 
were reapproximated and the patellar ligament was restored to its native position using 
two simple interrupted sutures of 5-0 PDS II absorbable suture (Ethicon).  Reflex 7 mm 
wound clips (Fine Science) were then used for wound closure.  A 1:1 mixture of New-
Skin Liquid Bandage and powdered metronidazole was then applied to the wound clips to 
assist in wound healing and prevent wound dehiscence.  Fluid loss was replaced using 
5% dextrose in 0.45% saline.  For pain management, buprenorphine was administered at 
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0.1 mg/kg intraperitoneally every eight hours for three days post-operation.  Wound clips 
were removed two weeks after the surgery.   
 
3.2.3 Microcomputed Tomography (µCT) 
Images of skeletal tissues were obtained using a Skyscan 1172 desktop imaging 
system (Skyscan-Bruker).  Scans were performed with an isotropic voxel size of 10 µm at 
65 kV and 200 µA through a 0.5mm aluminum filter.  Femoral trabecular parameters 
were measured in a 200 µm region of interest located approximately 50 µm proximal to 
the distal growth plate.  Femoral cortical parameters were measured within a 500 µm 
region of interest centered at the midshaft.  All bone analysis was performed in 
accordance with the American Society of Bone and Mineral Research (ASBMR) 
recommended parameters [178].   
 
3.2.4  Radiological Analysis 
Radiographs were acquired on the MX-20 Specimen Radiography System 
(Faxitron).  Radio tube voltage was set at 26 kV with a 15 sec exposure time.  Image 




Harvested tissues were fixed overnight at 4° C in 10% neutral-buffered formalin.  
Samples were then washed and placed into a decalcification solution of 14% EDTA for 
two weeks.  After decalcification, samples were paraffin embedded and cut at five-
micron thick sections.  Slides were stained in hematoxylin and eosin staining solution 
according to standard procedures.   
 
3.2.6 Torsional Mechanical Testing 
In order to determine the mechanical properties of healed fractures after the 
treatment protocol, torsional mechanical testing was employed using an Electroforce 
3100 System (Bose) with an attached torsional torque apparatus.  The each end of the 
femur was potted into molten woods metal and allowed to set in molds.  Upon hardening, 
the femur assembly was placed into fixtures attached to the torsional torque apparatus.  




3.3.1 ACVR2B/Fc Administration Increases Muscle 
Mass 
Soluble activin receptor administration induces a direct increase in skeletal 
muscle mass through muscle hypertrophy and hyperplasia.  This anabolism is the result 
of systemic myostatin inhibition.  As expected, ACVR2B/Fc treated mice gained muscle 
mass, which resulted an increase in body weight (18.1 ± 0.7%) (Figure 3.1).  In addition, 
the injured quadriceps gained 40.9 ± 5.0% in wet weight while the uninjured quadriceps 















































Figure 3.1: Weights with ACVR2B/Fc Treatment in Composite Injury Model 
Body weights of vehicle and ACVR2B/Fc treated mice (left).  Quadriceps weights of 
injured and uninjured limbs in vehicle and ACVR2B/Fc treated mice (right). 
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3.3.2 ACVR2B/Fc Administration Enhances Callus 
Formation 
In addition to gains in muscle mass, ACVR2B/Fc treatment also enhanced callus 
formation at the fracture site.  With ACVR2B/Fc administration, the callus bone volume 
was drastically enhanced (112 ± 19.7%) as compared to the vehicle treated mice.  
Additionally, the total mineral content was increased by 109 ± 19.8% with ACVR2B/Fc 
treatment.  The tissue mineral density, however, was unchanged with soluble activin 
















































































Figure 3.2: Fracture Callus Analysis 
Representative images of vehicle and ACVR2B/Fc treated eight weeks post-operation 
(top).  Callus bone volume, tissue mineral density, and total mineral content of injured 
femurs (bottom). 
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3.3.3 ACVR2B/Fc Treatment Does Not Affect 
Fracture Mechanical Properties 
Despite the tremendous increase in callus bone volume, upon torsion mechanical 
testing soluble activin receptor treatment did not enhance the mechanical properties of the 
fractured femur.  The maximum torque, stiffness, and ultimate energy were not 






Figure 3.3: Torsional Mechanical Testing Analysis 
Maximum torque (left), stiffness (center), and ultimate energy (right) of fracture 































































3.3.4 ACVR2B/Fc Treatment Enhances Volumetric 
Muscle Healing 
Similar to the anabolic effects seen in the bone, muscle healing was drastically 
enhanced with systemic activin blockade.  Histological sections of the injured quadriceps 
demonstrate dramatic improvement in muscle mass, reduction of muscle fibrosis, and 
minimization of fatty infiltrate (Figure 3.4).  This muscle hypertrophy and hyperplasia led 
to an increased number of regenerating myofibers with centrally located nuclei in the 






Figure 3.4: Histological Sections of Injured Muscle and Facture Callus 
Hematoxylin and eosin stained sections through fracture callus and injured muscle 
from vehicle (left) and ACVR2B/Fc (right) treated mice.   
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3.4 Discussion 
Activin signaling blockade is clearly a potent anabolic for both muscle and bone 
tissues, even in the setting of composite musculoskeletal injury.  Muscle healing as 
observed by histology is dramatically improved with ACVR2B/Fc treatment with 
increased muscle mass, reduced fibrosis, and reduced fat infiltrate.  These results are 
primarily due to ACVR2B/Fc’s strong affinity for mysotatin.  In addition to muscle 
anabolism, ACVR2B/Fc also dramatically affected the fracture callus.  The bone volume 
(112 ± 19.7%) and total mineral content (109 ± 19.8%) were significantly increased with 
soluble activin receptor treatment while the tissue mineral density was unaffected, 
indicating that there was no change in inherent tissue material properties.  However, 
when subjecting the fractured femurs to torsional testing, it was clear that ACVR2B/Fc 
treatment did not enhance the mechanical properties of the calluses despite the dramatic 
increases in bone volume.  When looking at histological sections through the fracture 
callus, there was abundant bone formation but the mineralized tissue was disorganized, 
woven bone and had not yet fully consolidated.  Additionally, histological sections 
demonstrated larger and more abundant areas of cartilage with ACVR2B/Fc treatment, 
indicating that the fracture callus had not fully mineralized and matured – likely 
attributing to the reduced mechanical properties. 
Ultimately, these studies demonstrate that soluble activin receptor treatment 
enhances callus bone volume and mineral content as well as improves volumetric muscle 
deficit healing in the setting of composite musculoskeletal injury.  The dual nature of this 
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potential treatment lends itself to possible synergy in healing between the bone and 
muscle compartments.  Despite these promising preliminary results, further investigation 
into the mechanism of ACVR2B/Fc’s anabolic effects and effective treatment protocol 
will be needed to determine if soluble activin receptor administration is a viable 
therapeutic option in the setting of composite muscle and bone injury. 
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Chapter 4  
4 Conclusions and Future Directions 
 
Through the studies discussed in this dissertation, it is clear that activin receptor 
signaling is an important regulator of both bone and muscle homeostasis.  Importantly, 
activin signaling is a negative regulator of skeletal tissues and acts in a manner similar to 
that exhibited in muscle.   
The experiments discussed demonstrate that the activin signaling components are 
present and functional within the osteoblasts.  Additionally, disruption of activin receptor 
signaling, using either pharmacological or genetic approaches, enhances osteoblast 
function and differentiation both in vitro and in vivo.  Through these analyses, it was 
determined that activin receptor type IIA (ACVR2A) is the primary signaling mediator in 
osteoblasts and disruption of this receptor leads to increased bone volume and enhanced 
mechanical properties.  The anabolic effect of ACVR2A disruption, however, cannot 
fully account for the full changes observed with systemic soluble activin receptor 
administration and represents approximately half of the total gains in bone volume.  The 
remaining anabolic fraction could be explained by a number of undefined factors, 
including hormonal changes, mechanical stimuli, and non-osteoblast effects.  Further 
investigation into these possibilities is necessary to fully understand the anabolic effects 
of systemic soluble activin receptor treatment.   
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Additional studies that target the activin type II receptors in other musculoskeletal 
cell types, such as osteoclasts and myoblasts, would also provide valuable information 
into the role of activin signaling within the musculoskeletal functional unit.  These 
studies would provide the relative contributions of each cell type to the total anabolic 
effect seen with systemic activin signaling blockade. 
Because pharmacological inhibition of activin signaling is known to induce bone 
and muscle increases, a logical extension would be to use soluble activin receptor 
administration to improve composite musculoskeletal injury healing.  In the setting of 
composite injury, systemic inhibition of activin signaling via ACVR2B/Fc demonstrated 
dramatic increases in callus bone volume and mineral content.  These changes, however, 
did not translate into enhanced mechanical strength of the fractured femurs, suggesting 
that the quality of the bone callus was diminished.  Upon further investigation, it became 
clear that the accelerated bone formation with ACVR2B/Fc treatment was not able to 
fully consolidate into hardy, lamellar bone in the post-surgical period.  Despite these 
results, soluble activin receptor treatment, however, did have profound effects in muscle 
healing.  ACVR2B/Fc administration significantly increased muscle size, reduced injury 
fibrosis, and reduced fatty infiltrate into the injury site.  Overall, further investigation into 
the mechanisms and dynamics of ACVR2B/Fc treatment in bone and muscle healing will 
be necessary to determine if ACVR2B/Fc is a vial therapeutic option for composite 
musculoskeletal injuries. 
Additional soluble activin receptor studies will be also necessary to determine the 
appropriate treatment dosing regimen to both enhance fracture callus development as 
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well as improve the mechanical properties of the healed bone.  A more precise treatment 
schedule may improve the callus quality and allow proper bone consolidation, which is 
necessary to yield a mechanical advantage.  Other additional studies in applying the 
composite injury model to transgenic mouse models, such as the osteoblast-specific 
ACVR2A/2B knockout, would also yield important information on the role of activin 
receptor signaling in the context of bone regeneration.  These cell-specific transgenic 
mouse models are powerful tools to dissect the major mechanisms of composite healing, 
and the proposed soluble activin receptor treatment studies are simply the beginning of 
our understanding of how activin signaling affects composite muscle and bone 
regeneration. 
In conclusion, the results of the studies discussed in this dissertation demonstrate 
that activin signaling in osteoblasts, which is primarily mediated through ACVR2A, acts 
a negative regulator of bone homeostasis, and activin-targeted biologics are potential dual 
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